Hirofumi Asano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hirofumi Asano has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Tatsuya Shimizu
Department of Neurosurgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
3 shared publications Kaoru Aishima
Department of Neurosurgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
2 shared publicationsMasahiko Tosaka
Department of Neurosurgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
2 shared publicationsRei Yamaguchi
Department of Neurosurgery and Gunma University Graduate School of Medicine, Maebashi, Gunma
2 shared publicationsYuhei Yoshimoto
Department of Neurosurgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
2 shared publicationsChinatsu Kakinuma
Department of Neurosurgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
1 shared publication
Latest Publications
- Open Access
- 17 August 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 12 (7)
Impact of endoscopy and related technologies on indications for transsphenoidal pituitary surgery for growth hormone–producing pituitary neuroendocrine tumors in McCune-Albright syndrome: illustrative case
BACKGROUND: McCune-Albright syndrome (MAS) is frequently associated with growth hormone (GH)–producing pituitary neuroendocrine tumors. However, transsphenoidal surgery is considered difficult because of skull base fibrous dysplasia, making complete tumor removal and endocrine remission challenging. OBSERVATIONS: Eighteen years earlier, a 31-year-old woman was diagnosed with MAS based on findings of GH hypersecretion, a café-au-lait spot on the back of her right shoulder, and bone lesions in the ribs and craniofacial bones. She had a pituitary tumor, but craniofacial fibrous dysplasia involving the sphenoid bone contraindicated surgical removal of the GH-producing pituitary tumor. Medical treatment was prioritized, and she underwent triple-drug therapy (octreotide, cabergoline, and pegvisomant) for 18 years. Insulin-like growth factor–1 remained poorly controlled. Recent advances in endonasal endoscopic surgery prompted reconsideration of surgical treatment. Endoscopic transnasal pituitary tumor resection using neuronavigation and a high-speed drill was performed, and achieved complete tumor resection, and all medical therapy became unnecessary. LESSONS: Surgical treatment was previously considered difficult in cases of GH-producing pituitary tumor associated with MAS. However, recent advances in transnasal endoscopic surgery, including drilling and neuronavigation techniques, have made surgical endocrine remission achievable in some cases. Therefore, surgical indications should be reconsidered even in patients undergoing medical therapy. https://thejns.org/doi/10.3171/CASE26521
- 17 August 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 12 (7)
Open AccessImpact of endoscopy and related technologies on indications for transsphenoidal pituitary surgery for growth hormone–producing pituitary neuroendocrine tumors in McCune-Albright syndrome: illustrative case
BACKGROUND: McCune-Albright syndrome (MAS) is frequently associated with growth hormone (GH)–producing pituitary neuroendocrine tumors. However, transsphenoidal surgery is considered difficult because of skull base fibrous dysplasia, making complete tumor removal and endocrine remission challenging. OBSERVATIONS: Eighteen years earlier, a 31-year-old woman was diagnosed with MAS based on findings of GH hypersecretion, a café-au-lait spot on the back of her right shoulder, and bone lesions in the ribs and craniofacial bones. She had a pituitary tumor, but craniofacial fibrous dysplasia involving the sphenoid bone contraindicated surgical removal of the GH-producing pituitary tumor. Medical treatment was prioritized, and she underwent triple-drug therapy (octreotide, cabergoline, and pegvisomant) for 18 years. Insulin-like growth factor–1 remained poorly controlled. Recent advances in endonasal endoscopic surgery prompted reconsideration of surgical treatment. Endoscopic transnasal pituitary tumor resection using neuronavigation and a high-speed drill was performed, and achieved complete tumor resection, and all medical therapy became unnecessary. LESSONS: Surgical treatment was previously considered difficult in cases of GH-producing pituitary tumor associated with MAS. However, recent advances in transnasal endoscopic surgery, including drilling and neuronavigation techniques, have made surgical endocrine remission achievable in some cases. Therefore, surgical indications should be reconsidered even in patients undergoing medical therapy. https://thejns.org/doi/10.3171/CASE26521
- Open Access
- 1 July 2024
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 8 (1)
Neurolymphomatosis secondary to primary central nervous system lymphoma: illustrative case
BACKGROUND: Neurolymphomatosis (NL) is a rare disease defined as an invasion of lymphoma into peripheral nerves, nerve roots, or nerve plexuses, including the cranial nerves. No clear treatment protocols have yet been defined for this pathology. OBSERVATIONS: A woman in her 40s had a primary central nervous system lymphoma diagnosed from an intracranial tumor biopsy and underwent chemotherapy and radiation therapy. After she complained of pain in the trunk and extremities, magnetic resonance imaging and [ 18 F]fluorodeoxyglucose (FDG) positron emission tomography (PET) performed 25 months after initial diagnosis revealed multiple lesions in the nerve ganglia, plexuses, and peripheral nerves from the cervical to the sacral spinal cord. Cerebrospinal fluid cytology revealed atypical lymphocytes and lymphoma dissemination in the spinal cavity. Based on these findings, NL was diagnosed. An intrathecal antineoplastic regimen temporarily reduced abnormal uptake of FDG, but the lesion recurred. After additional high-dose methotrexate therapy, FDG accumulation in the previously identified lesions disappeared. However, peripheral neuropathic pain and paraplegia remained. The patient died 9 months after the initial diagnosis of NL. LESSONS: The authors reported a case of NL following primary central nervous system lymphoma. In this case, FDG-PET proved useful for diagnosis, and high-dose methotrexate therapy was temporarily effective. https://thejns.org/doi/suppl/10.3171/CASE24107
- 1 July 2024
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 8 (1)
Open AccessNeurolymphomatosis secondary to primary central nervous system lymphoma: illustrative case
BACKGROUND: Neurolymphomatosis (NL) is a rare disease defined as an invasion of lymphoma into peripheral nerves, nerve roots, or nerve plexuses, including the cranial nerves. No clear treatment protocols have yet been defined for this pathology. OBSERVATIONS: A woman in her 40s had a primary central nervous system lymphoma diagnosed from an intracranial tumor biopsy and underwent chemotherapy and radiation therapy. After she complained of pain in the trunk and extremities, magnetic resonance imaging and [ 18 F]fluorodeoxyglucose (FDG) positron emission tomography (PET) performed 25 months after initial diagnosis revealed multiple lesions in the nerve ganglia, plexuses, and peripheral nerves from the cervical to the sacral spinal cord. Cerebrospinal fluid cytology revealed atypical lymphocytes and lymphoma dissemination in the spinal cavity. Based on these findings, NL was diagnosed. An intrathecal antineoplastic regimen temporarily reduced abnormal uptake of FDG, but the lesion recurred. After additional high-dose methotrexate therapy, FDG accumulation in the previously identified lesions disappeared. However, peripheral neuropathic pain and paraplegia remained. The patient died 9 months after the initial diagnosis of NL. LESSONS: The authors reported a case of NL following primary central nervous system lymphoma. In this case, FDG-PET proved useful for diagnosis, and high-dose methotrexate therapy was temporarily effective. https://thejns.org/doi/suppl/10.3171/CASE24107
- 5 April 2024
- Published by SAGE Publications in Interventional Neuroradiology
- Vol. 32 (4) , 1358-1364
Factors associated with decreasing diffusion-weighted imaging-positive area volume after mechanical thrombectomy in patients with large early ischemic changes
Objectives: This study aimed to evaluate the factors associated with decreasing diffusion-weighted imaging (DWI) positive areas in patients with large early ischemic changes after mechanical thrombectomy (MT). Materials and Methods: This retrospective single-center clinical study was conducted between January 2013 and December 2022. We included consecutive patients who underwent MT for acute large-vessel occlusion of the anterior circulation with low pretreatment DWI-Alberta Stroke Program Early Computed Tomography Scores (ASPECTS) (0–5), effective recanalization [thrombolysis in cerebral infarction (TICI) 2b or TICI3], and magnetic resonance imaging (MRI) acquired before and after MT. We measured the DWI-positive area volume before and after MT. The primary endpoint was the after/before-MT DWI-positive area–volume ratio. Results: In total, 28 patients were included in this study. Eight patients (29%) had an after/before-MT DWI-positive area–volume ratio of 2/s and 637 × 106 mm2/s, respectively ( p = 0.011). Multivariate logistic regression analysis showed that ADC level (OR, 1.020 [95% confidence intervals (CIs), 1.001–1.040]; p = 0.040) was an independent predictor of a decreased DWI-positive area after MT. There was a negative correlation between the mean ADC level and the after/before-MT DWI-positive area–volume ratio ( p < 0.001, | ρ| = 0.650), and the mean pretreatment ADC cutoff level was 649 × 106 mm2/s (area under the curve (AUC) = 0.806) for predicting a volume ratio of 6 mm2/s predicted a decreased DWI-positive area after MT.
- 5 April 2024
- Published by SAGE Publications in Interventional Neuroradiology
- Vol. 32 (4) , 1358-1364
Factors associated with decreasing diffusion-weighted imaging-positive area volume after mechanical thrombectomy in patients with large early ischemic changes
Objectives: This study aimed to evaluate the factors associated with decreasing diffusion-weighted imaging (DWI) positive areas in patients with large early ischemic changes after mechanical thrombectomy (MT). Materials and Methods: This retrospective single-center clinical study was conducted between January 2013 and December 2022. We included consecutive patients who underwent MT for acute large-vessel occlusion of the anterior circulation with low pretreatment DWI-Alberta Stroke Program Early Computed Tomography Scores (ASPECTS) (0–5), effective recanalization [thrombolysis in cerebral infarction (TICI) 2b or TICI3], and magnetic resonance imaging (MRI) acquired before and after MT. We measured the DWI-positive area volume before and after MT. The primary endpoint was the after/before-MT DWI-positive area–volume ratio. Results: In total, 28 patients were included in this study. Eight patients (29%) had an after/before-MT DWI-positive area–volume ratio of 2/s and 637 × 106 mm2/s, respectively ( p = 0.011). Multivariate logistic regression analysis showed that ADC level (OR, 1.020 [95% confidence intervals (CIs), 1.001–1.040]; p = 0.040) was an independent predictor of a decreased DWI-positive area after MT. There was a negative correlation between the mean ADC level and the after/before-MT DWI-positive area–volume ratio ( p < 0.001, | ρ| = 0.650), and the mean pretreatment ADC cutoff level was 649 × 106 mm2/s (area under the curve (AUC) = 0.806) for predicting a volume ratio of 6 mm2/s predicted a decreased DWI-positive area after MT.
- Open Access
- 1 January 2024
- Published by Japan Stroke Society in Japanese Journal of Stroke
- Vol. 46 (1) , 25-29
A case of major cerebral artery occlusion with acute myocardial infarction undergoing acute endovascular revascularization after percutaneous coronary intervention
89歳男性,突然の左上下肢麻痺を発症し,約40分で当院へ救急搬送された.来院時,JCS 2, 右共同偏視,左上下肢の重度麻痺を認め,NIHSS 21点であった.CTで右M1にhyperdense MCA signを認めたが,早期脳虚血性変化は認めなかった.心電図ではST上昇を認め,急性心筋梗塞に伴う心原性脳塞栓症と診断した.rt-PA静注療法は見送り,急性心筋梗塞に対する経皮的冠動脈形成術を行い,続いて脳血管撮影を行った.右中大脳動脈M1近位部閉塞を確認,血栓回収療法を行い,完全再開通が得られた.穿刺から再開通までは73分であった.治療後は左上下肢挙上可能となり,mRS 3で転院した.両疾患を合併した場合,治療の順序は症例ごとに検討が必要であるが,本症例は急性心筋梗塞の重症度が高いと判断し,優先して治療した.単純CTのみで診断しrt-PA静注療法を見送ったことで,治療時間短縮につながった.
- 1 January 2024
- Published by Japan Stroke Society in Japanese Journal of Stroke
- Vol. 46 (1) , 25-29
Open AccessA case of major cerebral artery occlusion with acute myocardial infarction undergoing acute endovascular revascularization after percutaneous coronary intervention
89歳男性,突然の左上下肢麻痺を発症し,約40分で当院へ救急搬送された.来院時,JCS 2, 右共同偏視,左上下肢の重度麻痺を認め,NIHSS 21点であった.CTで右M1にhyperdense MCA signを認めたが,早期脳虚血性変化は認めなかった.心電図ではST上昇を認め,急性心筋梗塞に伴う心原性脳塞栓症と診断した.rt-PA静注療法は見送り,急性心筋梗塞に対する経皮的冠動脈形成術を行い,続いて脳血管撮影を行った.右中大脳動脈M1近位部閉塞を確認,血栓回収療法を行い,完全再開通が得られた.穿刺から再開通までは73分であった.治療後は左上下肢挙上可能となり,mRS 3で転院した.両疾患を合併した場合,治療の順序は症例ごとに検討が必要であるが,本症例は急性心筋梗塞の重症度が高いと判断し,優先して治療した.単純CTのみで診断しrt-PA静注療法を見送ったことで,治療時間短縮につながった.
- 1 April 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (4) , 105626
Acute Endovascular Revascularization for Patients with Common Carotid Artery Occlusion Apparent on Cervical Magnetic Resonance Angiography
- 1 April 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (4) , 105626
Acute Endovascular Revascularization for Patients with Common Carotid Artery Occlusion Apparent on Cervical Magnetic Resonance Angiography